Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Hagstrom, E.

Refine Results

Resource Type

Availability

Creation Date

Author

Show more

Language

Search results

  • RSS Feed
(1 - 19 of 19)
Alirocumab and cardiovascular outcomes in patients with previous myocardial infarction
Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab
Associations of polymorphisms in the peroxisome proliferator-activated receptor gamma coactivator-1 alpha gene with subsequent coronary heart disease
2019 ESC/EAS Guidelines for the management of dyslipidaemias
Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome
2019 ESC/EAS guidelines for the management of dyslipidemias
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events A GENIUS-CHD Study of Individual Participant Data
Subsequent Event Risk in Individuals With Established Coronary Heart Disease Design and Rationale of the GENIUS-CHD Consortium
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study